CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity
Earn CME for related activities: https://www.naccme.com/oln
In this presentation from the 'Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas' symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Matthew J. Frigault discusses best practices for the management of cytokine release syndrome (CRS) and neurotoxicity when utilizing CAR-T therapy.
© 2019 Imedex, an HMP Company
Видео CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity канала HMP Education
In this presentation from the 'Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas' symposium at the 2019 Great Debates & Updates in Hematologic Malignancies in New York, Dr. Matthew J. Frigault discusses best practices for the management of cytokine release syndrome (CRS) and neurotoxicity when utilizing CAR-T therapy.
© 2019 Imedex, an HMP Company
Видео CAR-T: Management of Cytokine Release Syndrome and Neurotoxicity канала HMP Education
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Practical Application of Negative Pressure Wound Therapy with Instillation
The Patient Centered IBD Medical Home: Will This be the Future of IBD Healthcare Delivery?
Key Insights: Updates in Colorectal Cancer
Complex Clinical Cases: GI Bleeds
Key Insights: Novel Targets for IBD Therapy - Is This the Final Frontier?
Segment 2: Risk Assessment in Prostate Cancer
Update: Relapsed/Refractory Follicular Lymphoma
Mechanisms of Angiogenesis Inhibitors in Metastatic Colorectal Cancer
Virtual Patient Case: Carcinoid Syndrome #1 - Initial Presentation
Challenges Facing Medical Oncology Practice in the Next Decade
New agents/strategies on the horizon in bile duct cancer
What Determines “Quality” for Endoscopy Reporting in IBD Patients?
Optimizing Lumbar Discectomy: Closing Holes in the Disc
Expert Perspectives: MPN and MDS
Molecular Alterations and New Drugs in Bile Duct Cancer
Major Depressive Disorder: Leveraging the PCMH Model to Improve Patient-Centered Management
Multiple Myeloma Update: Maintenance Therapy
The Current Landscape of Biosimilars in IBD
Can We Increase the Immunogenicity in MSS CRC?
Optimizing Biological Therapies in the Modern Era
Key Insights in Chronic Lymphocytic Leukemia